Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) closed at $10.50 down -3.49% from its previous closing price of $10.88. In other words, the price has decreased by -$3.49 from its previous closing price. On the day, 1.26 million shares were traded. ARQT stock price reached its highest trading level at $11.08 during the session, while it also had its lowest trading level at $10.28.
Ratios:
For a deeper understanding of Arcutis Biotherapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.19 and its Current Ratio is at 8.46. In the meantime, Its Debt-to-Equity ratio is 1.11 whereas as Long-Term Debt/Eq ratio is at 1.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on August 28, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On January 03, 2024, Mizuho Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $4 to $8.
Mizuho Downgraded its Buy to Neutral on October 26, 2023, whereas the target price for the stock was revised from $57 to $4.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 03 ’24 when Welgus Howard G. bought 10,000 shares for $10.77 per share.
Burnett Patrick sold 1,728 shares of ARQT for $14,318 on Aug 19 ’24. The insider now owns 194,859 shares after completing the transaction at $8.29 per share. On Aug 19 ’24, another insider, Burnett Patrick, who serves as the Officer of the company, bought 1,728 shares for $8.29 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 1227355520 and an Enterprise Value of 1072481728. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.29 while its Price-to-Book (P/B) ratio in mrq is 6.56. Its current Enterprise Value per Revenue stands at 8.121 whereas that against EBITDA is -6.015.
Stock Price History:
Over the past 52 weeks, ARQT has reached a high of $13.17, while it has fallen to a 52-week low of $1.76. The 50-Day Moving Average of the stock is 8.56%, while the 200-Day Moving Average is calculated to be 37.47%.
Shares Statistics:
For the past three months, ARQT has traded an average of 2.62M shares per day and 2208560 over the past ten days. A total of 116.89M shares are outstanding, with a floating share count of 101.24M. Insiders hold about 13.39% of the company’s shares, while institutions hold 99.96% stake in the company. Shares short for ARQT as of 1723680000 were 23804159 with a Short Ratio of 9.08, compared to 1721001600 on 22664563. Therefore, it implies a Short% of Shares Outstanding of 23804159 and a Short% of Float of 25.2.
